Moraxella catarrhalis, a human respiratory tract pathogen

Clinical Infectious Diseases

Volumn 49, Issue 1, 2009, Pages 124-131

  Murphy, Timothy F ^a,b,c,d   Parameswaran, G Iyer ^a  

^a Division of Infectious Diseases   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d VA WESTERN NEW YORK HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; AZITHROMYCIN; BACTERIAL VACCINE; BETA LACTAMASE; CEFACLOR; CEFEPIME; CEFPODOXIME; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CLARITHROMYCIN; COTRIMOXAZOLE; LORACARBEF; MACROLIDE; MORAXELLA CATARRHALIS VACCINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE DERIVATIVE; UNCLASSIFIED DRUG;

AGE DISTRIBUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTEREMIA; BACTERIAL COLONIZATION; BACTERIUM CULTURE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DISEASE EXACERBATION; DISEASE TRANSMISSION; HOSPITAL INFECTION; HUMAN; IMMUNE RESPONSE; LOWER RESPIRATORY TRACT INFECTION; MICROBIOLOGICAL EXAMINATION; MORAXELLA CATARRHALIS; MORAXELLACEAE INFECTION; NONHUMAN; OTITIS MEDIA; PATHOGENESIS; PNEUMONIA; PREVALENCE; PRIORITY JOURNAL; RECURRENT INFECTION; REVIEW; SECRETORY OTITIS MEDIA; UNITED STATES; UPPER RESPIRATORY TRACT INFECTION;

ADULT; ANIMALS; BACTERIAL VACCINES; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; CHILD; CHILD, PRESCHOOL; HUMANS; INFANT; MORAXELLA (BRANHAMELLA) CATARRHALIS; MORAXELLACEAE INFECTIONS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY TRACT INFECTIONS; UNITED STATES; YOUNG ADULT;

EID: 66949164730     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/599375     Document Type: Review

References (70)

1. American Academy of Pediatrics. Diagnosis and management of acute otitis media. Pediatrics 2004; 113:1451-65.
2. Ruohola A, Meurman O, Nikkari S, et al. Microbiology of acute otitis media in children with tympanostomy tubes: prevalences of bacteria and viruses. Clin Infect Dis 2006;43:1417-22.
3. Arguedas A, Dagan R, Leibovitz E, Hoberman A, Pichichero M, Paris M. A multicenter, open label, double tympanocentesis study of high dose cefdinir in children with acute otitis media at high risk of persistent or recurrent infection. Pediatr Infect Dis J 2006;25:211-8.
4. Kilpi T, Herva E, Kaijalainen T, Syrjanen R, Takala AK. Bacteriology of acute otitis media in a cohort of Finnish children followed for the first two years of life. Pediatr Infect Dis J 2001;20:654-62.
5. McCarty J. A multicenter, open label trial of azithromycin for the treatment of children with acute otitis media. Pediatr Infect Dis J 1996;15: S10-4.
6. Aspin MM, Hoberman A, McCarty J, et al. Comparative study of the safety and efficacy of clarithromycin and amoxicillin-clavulanate in the treatment of acute otitis media in children. J Pediatr 1994; 125:136-41.
7. Chonmaitree T, Owen MJ, Patel JA, Hedgpeth D, Horlick D, Howie VM. Effect of viral respiratory tract infection on outcome of acute otitis media. J Pediatr 1992; 120:856-62.
8. DelBeccaro MA, Mendelman PM, Inglis AF, et al. Bacteriology ofacute otitis media: a new perspective. J Pediatr 1992; 120:81-4.
9. Faden H, Bernstein J, Stanievich J, Brodsky L, Ogra PL. Effect of prior antibiotic treatment on middle ear disease in children. Ann Otol Rhinol Laryngol 1992; 101:87-91.
10. Rodriguez WJ, Schwartz RH. Streptococcus pneumoniae causes otitis media with higher fever and more redness of tympanic membranes than Haemophilus influenzae or Moraxella catarrhalis. Pediatr Infect Dis J 1999; 18:942-4.
11. Faden H. The microbiologic and immunologic basis for recurrent otitis media in children. Eur J Pediatr 2001; 160:407-13.
12. Teele DW, Klein JO, Chase C, Menyuk P, Rosner BA; Greater Boston Otitis Media Study Group. Otitis media in infancy and intellectual ability, school achievement, speech, and language at age 7 years. J Infect Dis 1990; 162:685-94.
13. Post JC, Preston RA, Aul JJ, et al. Molecular analysis of bacterial pathogens in otitis media with effusion. JAMA 1995;273:1598-604.
14. Hendolin PH, Markkanen A, Ylikoski J, Wahlfors JJ. Use of multiplex PCR for simultaneous detection of four bacterial species in middle ear effusions. J Clin Microbiol 1997; 35:2854-8.
15. Hendolin PH, Paulin L, Ylikoski J. Clinically applicable multiplex PCR for four middle ear pathogens. J Clin Microbiol 2000; 38:125-32.
16. Hendolin PH, Karkkainen U, Himi T, Markkanen A, Ylikoski J. High incidence of Alloiococcus otitis in otitis media with effusion. Pediatr Infect Dis J 1999; 18:860-5.
17. Hall-Stoodley L, Hu FZ, Gieseke A, et al. Direct detection of bacterial biofilms on the middle-ear mucosa of children with chronic otitis media. JAMA 2006; 296:202-11.
18. Sethi S, Murphy TF. Infection in the pathogenesis and course ofchronic obstructive pulmonary disease. N Engl J Med 2008; 359:2355-65.
19. Larsen MV, Janner JH, Nielsen SD, Friis-Moller A, Ringbaek T, Lange P. Bacteriology in acute exacerbation ofchronic obstructive pulmonary disease in patients admitted to hospital. Scand J Infect Dis 2009;41:26-32.
20. Nicotra B, Rivera M, Luman JI, Wallace RJ. Branhamella catarrhalis as a lower respiratory tract pathogen in patients with chronic lung disease. Arch Intern Med 1986; 146:890-3.
21. Pollard JA, Wallace RJ Jr, Nash DR, Luman JI, Wilson RW. Incidence of Branhamella catarrhalis in the sputa of patients with chronic lung disease. Drugs 1986;31:103-8.
22. Monso E, Ruiz J, Rosell A, et al. Bacterial infection in chronic obstructive pulmonary disease: a study of stable and exacerbated outpatients using the protected specimen brush. Am J Respir Crit Care Med 1995; 152:1316-20.
23. Fagon J-Y, Chastre J, Trouillet J-L, et al. Characterization of distal bronchial microflora during acute exacerbation of chronic bronchitis. Am Rev Respir Dis 1990; 142:1004-8.
24. Soler N, Torres A, Ewig S, et al. Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation. Am J Respir Crit Care Med 1998;157:1498-505.
25. Sethi S, Evans N, Grant BJB, Murphy TF. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2002; 347:465-71.
26. Murphy TF, Brauer AL, Grant BJ, Sethi S. Moraxella catarrhalis in chronic obstructive pulmonary disease: burden ofdisease and immune response. Am J Respir Crit Care Med 2005; 172:195-9.
27. Sethi S, Wrona C, Eschberger K, Lobbins P, Cai X, Murphy TF. Inflammatory profile of new bacterial strain exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 177:491-7.
28. Sethi S, Muscarella K, Evans N, Klingman KL, Grant BJB, Murphy TF. Airway inflammation and etiology of acute exacerbations of chronic bronchitis. Chest 2000; 118:1557-65.
29. Chapman AJ, Musher DM, Jonsson S, Clarridge JE, Wallace RJ. Development of bactericidal antibody during Branhamella catarrhalis infection. J Infect Dis 1985; 151:878-82.
30. Murphy TF, Brauer AL, Aebi C, Sethi S. Antigenic specificity of the mucosal antibody response to Moraxella catarrhalis in chronic obstructive pulmonary disease. Infect Immun 2005; 73:8161-6.
31. Murphy TF, Brauer AL, Aebi C, Sethi S. Identification of surface antigens of Moraxella catarrhalis as targets of human serum antibody responses in chronic obstructive pulmonary disease. Infect Immun 2005; 73:3471-8.
32. Bakri F, Brauer AL, Sethi S, Murphy TF. Systemic and mucosal antibody response to Moraxella catarrhalis following exacerbations of chronic obstructive pulmonary disease. J Infect Dis 2002; 185:632-40.
33. Zalacain R, Sobradillo V, Amilibia J, et al. Predisposing factors to bacterial colonization in chronic obstructive pulmonary disease. Eur Respir J 1999; 13:343-8.
34. Wald ER. Microbiology of acute and chronic sinusitis in children and adults. Am J Med Sci 1998;316:13-20.
35. Clinical practice guideline: management of sinusitis. Pediatrics 2001 ; 108:798-808.
36. Brook I, Foote PA, Hausfeld JN. Frequency of recovery of pathogens causing acute maxillary sinusitis in adults before and after introduction of vaccination of children with the 7-valent pneumococcal vaccine. J Med Microbiol 2006; 55:943-6.
37. Wright PW, Wallace RJ Jr. Pneumonia due to Moraxella (Branhamella) catarrhalis. Semin Respir Infect 1989; 4:40-6.
38. Tolentino LF. Causes of Moraxella catarrhalis pathogenicity: review of literature and hospital epidemiology. Laboratory Medicine 2007;38: 420-1.
39. Abuhammour WM, Abdel-Haq NM, Asmar BI, Dajani AS. Moraxella catarrhalis bacteremia: a 10-year experience. South Med J 1999;92:1071-4.
40. Vaneechoutte M, Verschraegen G, Claeys G, Weise B, Van den Abeele AM. Respiratory tract carrier rates of Moraxella (Branhamella) catarrhalis in adults and children and interpretation of the isolation of M. catarrhalis from sputum. J Clin Microbiol 1990; 28:2674-80.
41. Ejlertsen T, Thisted E, Ebbesen F, Olesen B, Renneberg J. Branhamella catarrhalis in children and adults: a study of prevalence, time of colonisation, and association with upper and lower respiratory tract infections. J Infect 1994;29:23-31.
42. Faden H, Harabuchi Y, Hong JJ, Pediatrics TW. Epidemiology of Moraxella catarrhalis in children during the first 2 years of life: relationship to otitis media. J Infect Dis 1994; 169:1312-7.
43. Aniansson G, Alm B, Andersson B, et al. Nasopharyngeal colonization during the first year of life. J Infect Dis 1992; 165:S38-42.
44. Leach AJ, Boswell JB, Asche V, Nienhuys TG, Mathews JD. Bacterial colonization of the nasopharynx predicts very early onset and persistence of otitis media in Australian Aboriginal infants. Pediatr Infect Dis J 1994; 13:983-9.
45. Block SL, Hedrick J, Harrison CJ, et al. Community-wide vaccination with the heptavalent pneumococcal conjugate significantly alters the microbiology of acute otitis media. Pediatr Infect Dis J 2004; 23:829-33.
46. Casey JR, Pichichero ME. Changes in frequency and pathogens causing acute otitis media in 1995-2003. Pediatr Infect Dis J 2004; 23:824-8.
47. Revai K, McCormick DP, Patel J, Grady JJ, Saeed K, Chonmaitree T. Effect of pneumococcal conjugate vaccine on nasopharyngeal bacterial colonization during acute otitis media. Pediatrics 2006; 117:1823-9.
48. Hays JP, Eadie K, Veenhoven R, Verduin CM, Verbrugh H, van Belkum A. Pneumococcal vaccination does not affect the genetic diversity of Moraxella catarrhalis isolates in children. Eur J Clin Microbiol Infect Dis 2004;23:801-3.
49. Brook I, Gober AE. Frequency of recovery of pathogens from the nasopharynx of children with acute maxillary sinusitis before and after the introduction of vaccination with the 7-valent pneumococcal vaccine. Int J Pediatr Otorhinolaryngol 2007; 71:575-9.
50. Masaki H, Asoh N, Kawazoe K, et al. Possible relationship of PFGE patterns of Moraxella catarrhalis between hospital- and community- acquired respiratory infections in a community hospital. Microbiol Immunol 2003; 47:379-85.
51. Levy F, Leman SC, Sarubbi FA, Walker ES. Nosocomial transmission clusters and risk factors in Moraxella catarrhalis. Epidemiol Infect 2009; 137:581-90.
52. Patterson TF, Patterson JE, Masecar BL, Barden GE, Hierholzer WJ Jr, Zervos MJ. A nosocomial outbreak of Branhamella catarrhalis confirmed by restriction endonuclease analysis. J Infect Dis 1988;157:996-1001.
53. Richards SJ, Greening AP, Enright MC, Morgan MG, McKenzie H. Outbreak of Moraxella catarrhalis in a respiratory unit. Thorax 1993;48:91-2.
54. Hays JP, Eadie K, Verduin CM, Hazelzet J, Verbrugh H, van Belkum A. Changes in genetic types and population dynamics of Moraxella catarrhalis in hospitalized children are not associated with an exacerbation of existing disease. J Med Microbiol 2003; 52:815-20.
55. Bootsma HJ, van der Heide HG, van de Pas S, Schouls LM, Mooi FR. Analysis of Moraxella catarrhalis by DNA typing: evidence for a distinct subpopulation associated with virulence traits. J Infect Dis 2000; 181:1376-87.
56. Hays JP, Gorkink R, Simons G, et al. High-throughput amplification fragment length polymorphism (htAFLP) analysis identifies genetic lineage markers but not complement phenotype-specific markers in Moraxella catarrhalis. Clin Microbiol Infect 2007; 13:55-62.
57. Wirth T, Morelli G, Kusecek B, et al. The rise and spread of a new pathogen: seroresistant Moraxella catarrhalis. Genome Res 2007;17:1647-56.
58. Verhaegh SJ, Streefland A, Dewnarain JK, Farrell DJ, van Belkum A, Hays JP. Age-related genotypic and phenotypic differences in Moraxella catarrhalis isolates from children and adults presenting with respiratory disease in 2001-2002. Microbiology 2008; 154:1178-84.
59. Slevogt H, Seybold J, Tiwari KN, et al. Moraxella catarrhalis is internalized in respiratory epithelial cells by a trigger-like mechanism and initiates a TLR2- and partly NOD1-dependent inflammatory immune response. Cell Microbiol 2007; 9:694-707.
60. Heiniger N, Spaniol V, Troller R, Vischer M, Aebi C. A reservoir of Moraxella catarrhalis in human pharyngeal lymphoid tissue. J Infect Dis 2007; 196:1080-7.
61. Nordstrom T, Blom AM, Tan TT, Forsgren A, Riesbeck K. Ionic binding of C3 to the human pathogen Moraxella catarrhalis is a unique mechanism for combating innate immunity. J Immunol 2005; 175:3628-36.
62. Attia AS, Ram S, Rice PA, Hansen EJ. Binding of vitronectin by the Moraxella catarrhalis UspA2 protein interferes with late stages of the complement cascade. Infect Immun 2006; 74:1597-611.
63. Pearson MM, Laurence CA, Guinn SE, Hansen EJ. Biofilm formation by Moraxella catarrhalis in vitro: roles of the UspA1 adhesin and the Hag hemagglutinin. Infect Immun 2006;74:1588-96.
64. Slevogt H, Schmeck B, Jonatat C, et al. Moraxella catarrhalis induces inflammatory response of bronchial epithelial cells via MAPK and NF- KB activation and histone deacetylase activity reduction. Am J Physiol Lung Cell Mol Physiol 2006; 290:L818-26.
65. Edwards KJ, Schwingel JM, Datta AK, Campagnari AA. Multiplex PCR assay that identifies the major lipooligosaccharide serotype expressed by Moraxella catarrhalis clinical isolates. J Clin Microbiol 2005; 43: 6139-43.
66. Bootsma HJ, van Dijk H, Vauterin P, Verhoef J, Mooi FR. Genesis of b-lactamase-producing Moraxella catarrhalis: evidence for transformation-mediated horizontal transfer. Mol Microbiol 2000; 36:93-104.
67. Deshpande LM, Sader HS, Fritsche TR, Jones RN. Contemporary prevalence of BRO b-lactamases in Moraxella catarrhalis: report from the SENTRY antimicrobial surveillance program (North America, 1997 to 2004). J Clin Microbiol 2006;44:3775-7.
68. Sahm DF, Brown NP, Thornsberry C, Jones ME. Antimicrobial susceptibility profiles among common respiratory tract pathogens: a GLOBAL perspective. Postgrad Med 2008; 120(3 Suppl 1):16-24.
69. Prymula R, Peeters P, Chrobok V, et al. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet 2006; 367:740-8.
70. Ruckdeschel EA, Kirkham C, Lesse AJ, Hu Z, Murphy TF. Mining the Moraxella catarrhalis genome: identification of potential vaccine antigens expressed during human infection. Infect Immun 2008;76:1599-607.